Severe Asthma Market Size is Anticipated to Surpass USD 7 Billion by 2032 | DelveInsight

Nevada (Las Vegas), United States, DelveInsight’s “Severe Asthma – Market Insight, Epidemiology and Market Forecast – 2032” report provides current treatment practices, emerging drugs, Severe Asthma market share of the individual therapies, current and forecasted Severe Asthma market size from 2019 to 2032 segmented by seven major markets. The report also offers current Severe Asthma therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Severe Asthma market.

Severe Asthma Overview
Asthma is the most common chronic respiratory disease worldwide. It affects the lungs’ airways, which become inflamed and narrowed as a result of various triggers, making it difficult for air to flow out. A complex interaction of airway inflammation and remodelling results in airway hyper-responsiveness (AHR), which leads to variable and excessive airway contraction. Wheezing, shortness of breath, coughing, a feeling of tightness in the chest, straining of the neck and chest muscles, rapid breathing, and changes in heart rate are all common Asthma symptoms.

Severe Asthma Epidemiological Insights
The disease epidemiology covered in the report provides historical and forecasted Severe Asthma epidemiology segmented as the Total Diagnosed Prevalent (adult + pediatric) Cases of Asthma, Severity-specific Diagnosed Prevalent Cases of Asthma, and Type-specific Diagnosed Prevalent Cases of Severe Asthma. The report includes the Severe Asthma scenario in the 7MM, covering the United States, the EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

As per the assessment of DelveInsight, the total diagnosed prevalent (adult + pediatric) cases of Asthma in the 7MM was observed to be approximately 54 million cases in 2021. These cases are expected to increase by 2032. As per DelveInsight’s estimates, among 7MM, the United States had the highest diagnosed cases of adult Asthma with almost 20 million cases in 2021.

Severe Asthma Treatment Market
The fundamental goal of Asthma therapy is to minimize airway inflammation and also reduce the Asthma symptoms that come with it. Guidelines-based care focuses on illness severity and selecting the appropriate medicinal therapy to reduce the likelihood of exacerbation. Although inhaled corticosteroids are the most commonly used chronic asthma treatment, quick-relief (reliever) or rescue medications are frequently used to alleviate acute asthma symptoms.

There are currently six monoclonal antibodies approved by the US FDA for use as add-on biological Severe Asthma treatment. They include Cinqair (reslizumab) Teva Pharmaceutical, Dupixent (dupilumab) Sanofi, and Regeneron, Fasenra (benralizumab) AstraZeneca/Kyowa Kirin, Tezspire (tezepelumab) AstraZeneca and Amgen, Nucala (mepolizumab) GlaxoSmithKline, and Xolair (omalizumab) Novartis/Genentech.

Promising Therapies in the Severe Asthma Pipeline
• GSK3511294
• PT010
• PT027
• CSJ117
• MRx-4DP0004
• RG6173
• CBP-201
• PRS-060/AZD1402
• BSI-045B
• AVTX-002

Discover more about Severe Asthma therapies in the pipeline @ Severe Asthma Drugs

Leading Companies Working in the Severe Asthma Market
• GSK
• AstraZeneca
• Avillion
• 4D Pharma
• Avalo Therapeutics
• Biosion
• Roche
• GenenTech
• Boehringer Ingelheim Pharmaceuticals
• Amgen
• Pfizer
• AB Science
• Teva Pharmaceuticals
• Sanofi
• Regeneron Pharmaceuticals
• Pieris Pharma
• Novartis
• Theravance Biopharma

Learn more about the recent developments and breakthroughs in the Severe Asthma market @ Severe Asthma Clinical Trials

Severe Asthma Market Dynamics
The growth of the Severe Asthma market in the coming years will be determined by several factors, including an increase in the diagnosed prevalence of Severe Asthma and an increase in demand for personalized therapies. In addition, the development of well-designed, randomized, controlled non-crossover trials with potential patient benefits will drive the growth of the Severe Asthma market during the forecast period. Furthermore, new drug approvals and entry will alter the Severe Asthma market dynamics in the future. Several pharmaceutical behemoths are researching drugs for Severe Asthma treatment with an improved diagnostic approach, which will lead to an increase in the Severe Asthma market in the coming years.

As per DelveInsight’s analysis, the Severe Asthma market size in the 7MM was valued at almost USD 6 Billion in 2021 and is anticipated to grow at a CAGR of 5% for the study period (2019-2032).

On the other hand, a lack of effective specific treatments for non-eosinophilic asthma (NEA) may represent an orphan asthma endotype, posing a challenge to the growth of the Severe Asthma market. Other factors, such as a high cost of treatment, limitations in diagnosis, incorrect inhaler techniques, and poor adherence to treatment, can all be considered as potential barriers to the rise of the Severe Asthma market.

Scope of the Severe Asthma Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, Japan]
Key Severe Asthma Companies: GSK, AstraZeneca, Avillion, 4D Pharma, Avalo Therapeutics, Biosion, Roche, GenenTech, Boehringer Ingelheim Pharmaceuticals, Amgen, Pfizer, AB Science, Teva Pharmaceuticals, Sanofi, Regeneron Pharmaceuticals, Pieris Pharma, Novartis, Theravance Biopharma, and others
Key Severe Asthma Pipeline Therapies: GSK3511294, PT010, PT027, CSJ117, MRx-4DP0004, RG6173, CBP-201, PRS-060/AZD1402, BSI-045B, AVTX-002, and others
Therapeutic Assessment: Severe Asthma current marketed and emerging therapies
Severe Asthma Market Dynamics: Severe Asthma market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis and Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Severe Asthma Market Access and Reimbursement

Table of Contents
1. Severe Asthma Market Key Insights
2. Severe Asthma Market Report Introduction
3. Severe Asthma Market Overview at a Glance
4. Severe Asthma Market Executive Summary
5. Disease Background and Overview
6. Severe Asthma Treatment and Management
7. Severe Asthma Epidemiology and Patient Population
8. Patient Journey
9. Severe Asthma Emerging Drugs
10. 7MM Severe Asthma Market Analysis
11. Severe Asthma Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Severe Asthma Market Drivers
15. Severe Asthma Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Sandeep Joshi
info@delveinsight.com
+1(919)321-6187